Drug interactions
Mitoxantrone + Regorafenib
Severity: Moderate
Mitoxantrone and Regorafenib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Mitoxantrone is a BCRP substrate, and regorafenib may inhibit BCRP. This could raise mitoxantrone exposure and increase myelosuppression and cardiotoxicity.
What this interaction means in plain words
Mitoxantrone and Regorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Mitoxantrone belongs to Central Nervous System; Regorafenib belongs to Oncology.
Why it happens
Inhibition of BCRP (ABCG2) efflux transport by regorafenib, reducing mitoxantrone clearance.
What to do
Monitor blood counts and cardiac function (LVEF) closely. Consider mitoxantrone dose reduction if toxicity emerges.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Mitoxantrone and Regorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Mitoxantrone
Other interactions of Regorafenib
Frequently asked questions
Can I take Mitoxantrone with Regorafenib?
MediHelp rates the interaction as moderate. Mitoxantrone and Regorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Mitoxantrone is a BCRP substrate, and regorafenib may inhibit BCRP. This could raise mitoxantrone exposure and increase myelosuppression and cardiotoxicity.
How serious is the interaction between Mitoxantrone and Regorafenib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and cardiac function (LVEF) closely. Consider mitoxantrone dose reduction if toxicity emerges.
What other medicines interact with Mitoxantrone?
MediHelp also lists interactions of Mitoxantrone with, for example, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel, Belatacept. The full list is on the Mitoxantrone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
